Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul G Kluetz

Showing results (1-10 of 150) with videos related to

Pageof 15
Sort By:
Seminars in Oncology|March 13, 2016
Looking to the future in an unprecedented time for cancer drug developmentPaul G Kluetz, Richard Pazdur
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Neoadjuvant breast cancer therapy and drug developmentPatricia Cortazar, Paul G Kluetz
Journal of the National Cancer Institute|July 28, 2022
Encouraging Rigorous Patient-Generated Data All Along the Drug Development ContinuumVishal Bhatnagar, Paul G Kluetz
Clinical Advances in Hematology & Oncology : H&O|February 17, 2021
The FDA's patient-focused drug development initiativePaul G Kluetz, Vishal Bhatnagar
Radiologic Clinics of North America|February 28, 2006
Acute pulmonary embolism: imaging in the emergency departmentPaul G Kluetz, Charles S White
Lung Cancer (Amsterdam, Netherlands)|February 5, 2008
Successful treatment of small cell lung cancer during pregnancyPaul G Kluetz, Martin J Edelman
Nature Reviews. Clinical Oncology|April 11, 2025
FDA approvals in 2024: new options for patients across cancer types and therapeutic classesSundeep Agrawal, Esther Park, Paul G Kluetz
The Lancet. Oncology|May 5, 2018
Incorporating the patient experience into regulatory decision making in the USA, Europe, and CanadaPaul G Kluetz, Daniel J O'Connor, Katherine Soltys
The Oncologist|May 31, 2022
Blurring the Lines of Design: Prospective Observational Cohorts and Pragmatic Clinical Trials Characterizing Treatment Effects in Routine Cancer CareDonna R Rivera, Erin Larkins, Paul G Kluetz
The New England Journal of Medicine|June 28, 2018
Metastasis-free Survival - A New End Point in Prostate Cancer TrialsJulia A Beaver, Paul G Kluetz, Richard Pazdur
Pageof 15

Showing results (1-10 of 150) with videos related to

Sort By:
Pageof 15
Seminars in Oncology|March 13, 2016
Looking to the future in an unprecedented time for cancer drug developmentPaul G Kluetz, Richard Pazdur
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Neoadjuvant breast cancer therapy and drug developmentPatricia Cortazar, Paul G Kluetz
Journal of the National Cancer Institute|July 28, 2022
Encouraging Rigorous Patient-Generated Data All Along the Drug Development ContinuumVishal Bhatnagar, Paul G Kluetz
Clinical Advances in Hematology & Oncology : H&O|February 17, 2021
The FDA's patient-focused drug development initiativePaul G Kluetz, Vishal Bhatnagar
Radiologic Clinics of North America|February 28, 2006
Acute pulmonary embolism: imaging in the emergency departmentPaul G Kluetz, Charles S White
Lung Cancer (Amsterdam, Netherlands)|February 5, 2008
Successful treatment of small cell lung cancer during pregnancyPaul G Kluetz, Martin J Edelman
Nature Reviews. Clinical Oncology|April 11, 2025
FDA approvals in 2024: new options for patients across cancer types and therapeutic classesSundeep Agrawal, Esther Park, Paul G Kluetz
The Lancet. Oncology|May 5, 2018
Incorporating the patient experience into regulatory decision making in the USA, Europe, and CanadaPaul G Kluetz, Daniel J O'Connor, Katherine Soltys
The Oncologist|May 31, 2022
Blurring the Lines of Design: Prospective Observational Cohorts and Pragmatic Clinical Trials Characterizing Treatment Effects in Routine Cancer CareDonna R Rivera, Erin Larkins, Paul G Kluetz
The New England Journal of Medicine|June 28, 2018
Metastasis-free Survival - A New End Point in Prostate Cancer TrialsJulia A Beaver, Paul G Kluetz, Richard Pazdur
Pageof 15